A 6-MONTH, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP, MAINTENANCE OF EFFECT STUDY OF ESREBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006760-10

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of ESRBX (QD) compared with placebo treatment in assessing the maintenance of effect for the treatment of pain intensity and function associated with fibromyalgia.


Critère d'inclusion

  • Esreboxetine is being developed for the treatment of fibromyalgia

Liens